What is CLDX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 2.35B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CLDX?

P/E (TTM) is n/a and 52-week range is $22.10 to $45.14 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CLDX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CLDX?

The company profile lists revenue (TTM) near $157K, net income (TTM) near $-23.20B, EPS (TTM) near $-4.36 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Celldex Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Hampton, New Jersey, US, 78.5M shares outstanding, ISIN US15117B2025 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Celldex Therapeutics Inc

$CLDX

Health Care · Biotechnology

IR Run Scenarios

$29.89

+2.01%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. The company is headquartered in Hampton, New Jersey and currently employs 198 full-time employees. The firm is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.

Employees

198

Website

celldex.com/

IPO

1986-05-15

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)